Thursday, 7 November 2019

Nanoparticles - Metal & Metal Oxides Market - Top Manufacturers Report


Nov 08, 2019- Million Insights Market Research has published a new report titledNanoparticles - Metal & Metal Oxides Market – Global Industry Analysis, Size, Share, Growth, and Forecast, 2018–2026.’ Nanoparticles - Metal & Metal Oxides market report helps analyze trends and significant developments in the industry.
The global Nanoparticles - Metal & Metal Oxides Market in Healthcare was worth USD 25.86 billion in 2016 which is anticipated to reach USD 80.74 billion over the forecast period. The existence of a significant amount of metal and metal oxide nanoparticle based drugs that are authorized by the U.S. FDA and prescribed by physicians for the treatment of acute and chronic ailments is attributive for the estimated market.


Furthermore, presence of molecules in the development phase based on the principle of metal oxide nanoparticles is anticipated to boost growth in the coming years. Applications served by these particles include radiotherapy enhancement, drug & gene therapy, thermal ablation, and sensitive diagnostic assay.
This versatile nature with respect to the applicability in health care makes these particles a substantial source of growth in nanomedicine market. Technological innovations pertaining to reduction of adverse effects linked to the application of these particles is expected to influence growth in the forecasted period.
Scientists and biologists are currently involved in directing R&D to improve understanding of metal based nanoparticles in order to lessen the toxicity problems associated with their usage. Subsequent developments are anticipated to fast-track the development over the forecast period.
In-vivo imaging is projected to contribute for the largest share in terms of revenue due to growing adoption of nanoshells, for example, Au3Cu1 that claims to provide better contrast for blood vessels which can be used in vivo MR angiography.
Key companies working for the development of metal and metal oxide nanoparticles include Nanobiotix, AstraZeneca, Pfizer Inc., nanoComposix, Merck KGaA, Nanospectra Biosciences, Immunolight LLC, Women’s Hospital and Brigham.
Pharma-biotech entities are engaged in R&D and are carrying out enormous capital investments. Product advancement in human therapeutics and rising demand for better outcomes by the treatment provided are anticipated to boost progress in the coming years.

No comments:

Post a Comment